null Investors Careers Press Events Search Follow us Contact us About Recipharm Manufacturing Development & Technology DEVELOPMENT MANUFACTURING CORPORATE FILM INVESTORS ANNUAL GENERAL MEETING 2015 NEWSFEED 2015-09-07 Recipharm in discussions with Alcon regarding long-term manufacturing agreement 2015-08-26 Recipharm Signs Agreement with RedHill Biopharma for Manufacturing of RHB-105 for treatment of H. pylori infection Recipharm AB, Stockholm, today announces that it has signed an agreement with Israeli biopharmaceutical company RedHill Biopharma Ltd (TASE/NASDAQ: RDHL) (“RedHill”) for the manufacturing of RedHill’s leading, late-stage patented drug candidate, RHB-105. RHB-105 is being developed for the treatment of Helicobacter pylori (H. pylori) bacterial infection, a global market estimated at about $4.8 billion. Recipharm will be responsible for the supply of the remaining clinical trial material and ongoing future commercial supply. More © 2015 Recipharm AB (publ). All rights reserved Recipharm AB (publ) Lagervägen 7 SE-136 50 Jordbro Sweden. T: 46 8 602 52 00. info@recipharm.com Site Map |Website terms| Privacy Policy | Cookies We use cookies to ensure that we give you the best experience on our website. Ok